B.G. Negev Technologies Ltd., the technology commercialization company of Ben-Gurion University, signed a cooperation agreement with the German company Curasan AG, for the joint development of matrices to accelerate the bone tissue healing process. The German company will initially invest about 900,000 euros in the research carried out by Dr. Hana Rappaport and her team at Ben-Gurion University.
The research team led by Dr. Rappaport from the Department of Biotechnology Engineering at the university, developed an innovative matrix that was registered as a patent, based on peptides (a special structure of protein), through which the healing and growth processes of bones can be significantly improved. As part of the joint research, Curasan and Dr. Rapaport will combine products based on existing inorganic minerals of the German company with the peptide matrices for bone regeneration developed at Ben-Gurion University, with the aim of developing and producing a variety of biomaterials for orthopedic and dental uses.
"The funding allocated for this purpose will allow us to develop a new generation of products that will significantly strengthen the field of accelerating bone healing, while still maintaining the characteristics provided by our inorganic products," explains Dr. Fabian Peters, director of research and development for tissue restoration at Curasan AG .
Dr. Hana Rappaport states that "the goal of the joint research is to create a variety of unique products capable of accelerating the process of bone tissue regeneration, which will combine the peptide compounds of Ben-Gurion University with the products of the Curasan AG company, will support the body's self-healing process and cause for optimal regeneration of the bone".
